Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.98 +0.33 (+1.77%)
Delayed Quote Updated: 10:15 AM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
5 Analysts Have This To Say About Legend Biotech ↗
 
Via Benzinga
News headline image
What Does the Market Think About Legend Biotech? ↗
 
Via Benzinga
News headline image
Demystifying Legend Biotech: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Is Legend Biotech Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Peering Into Legend Biotech's Recent Short Interest ↗
 
Via Benzinga
News headline image
Where Legend Biotech Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
Breaking Down Legend Biotech: 9 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
(LEGN) - Analyzing Legend Biotech's Short Interest ↗
 
Via Benzinga
News headline image
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
9 Analysts Have This To Say About Legend Biotech ↗
 
Via Benzinga
News headline image
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Where Legend Biotech Stands With Analysts ↗
 
Via Benzinga
News headline image
Peering Into Legend Biotech's Recent Short Interest ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock ↗
 
Via Benzinga
News headline image
Looking Into Legend Biotech's Recent Short Interest ↗
 
Via Benzinga
News headline image
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
Newly created position to lead efforts focused on continued growth and sales 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients ↗
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
Via Benzinga
News headline image
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma ↗
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
News headline image
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.